213 related articles for article (PubMed ID: 31096265)
1. The Relationship of Varenicline Agonism of α4β2 Nicotinic Acetylcholine Receptors and Nicotine-Induced Dopamine Release in Nicotine-Dependent Humans.
McCaul ME; Wand GS; Kuwabara H; Dannals RF; Wong D; Xu X
Nicotine Tob Res; 2020 May; 22(6):892-899. PubMed ID: 31096265
[TBL] [Abstract][Full Text] [Related]
2. The contribution of agonist and antagonist activities of α4β2* nAChR ligands to smoking cessation efficacy: a quantitative analysis of literature data.
Rollema H; Hurst RS
Psychopharmacology (Berl); 2018 Sep; 235(9):2479-2505. PubMed ID: 29980822
[TBL] [Abstract][Full Text] [Related]
3. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.
Gonzales D; Rennard SI; Nides M; Oncken C; Azoulay S; Billing CB; Watsky EJ; Gong J; Williams KE; Reeves KR;
JAMA; 2006 Jul; 296(1):47-55. PubMed ID: 16820546
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers.
Nakamura M; Oshima A; Fujimoto Y; Maruyama N; Ishibashi T; Reeves KR
Clin Ther; 2007 Jun; 29(6):1040-56. PubMed ID: 17692720
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers.
Tsai ST; Cho HJ; Cheng HS; Kim CH; Hsueh KC; Billing CB; Williams KE
Clin Ther; 2007 Jun; 29(6):1027-39. PubMed ID: 17692719
[TBL] [Abstract][Full Text] [Related]
7. Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum.
Bordia T; Hrachova M; Chin M; McIntosh JM; Quik M
J Pharmacol Exp Ther; 2012 Aug; 342(2):327-34. PubMed ID: 22550286
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial.
Jorenby DE; Hays JT; Rigotti NA; Azoulay S; Watsky EJ; Williams KE; Billing CB; Gong J; Reeves KR;
JAMA; 2006 Jul; 296(1):56-63. PubMed ID: 16820547
[TBL] [Abstract][Full Text] [Related]
9. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt.
West R; Baker CL; Cappelleri JC; Bushmakin AG
Psychopharmacology (Berl); 2008 Apr; 197(3):371-7. PubMed ID: 18084743
[TBL] [Abstract][Full Text] [Related]
10. Smoking cessation efficacy and safety of varenicline, an alpha4beta2 nicotinic receptor partial agonist.
Tonstad S
J Cardiovasc Nurs; 2006; 21(6):433-6. PubMed ID: 17293731
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence.
Rollema H; Shrikhande A; Ward KM; Tingley FD; Coe JW; O'Neill BT; Tseng E; Wang EQ; Mather RJ; Hurst RS; Williams KE; de Vries M; Cremers T; Bertrand S; Bertrand D
Br J Pharmacol; 2010 May; 160(2):334-45. PubMed ID: 20331614
[TBL] [Abstract][Full Text] [Related]
12. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice.
Bagdas D; Alkhlaif Y; Jackson A; Carroll FI; Ditre JW; Damaj MI
Neuropharmacology; 2018 Aug; 138():72-79. PubMed ID: 29860196
[TBL] [Abstract][Full Text] [Related]
13. PET imaging of high-affinity α4β2 nicotinic acetylcholine receptors in humans with 18F-AZAN, a radioligand with optimal brain kinetics.
Wong DF; Kuwabara H; Kim J; Brasic JR; Chamroonrat W; Gao Y; Valentine H; Willis W; Mathur A; McCaul ME; Wand G; Gean EG; Dannals RF; Horti AG
J Nucl Med; 2013 Aug; 54(8):1308-14. PubMed ID: 23801676
[TBL] [Abstract][Full Text] [Related]
14. Neural Signatures of Cognitive Flexibility and Reward Sensitivity Following Nicotinic Receptor Stimulation in Dependent Smokers: A Randomized Trial.
Lesage E; Aronson SE; Sutherland MT; Ross TJ; Salmeron BJ; Stein EA
JAMA Psychiatry; 2017 Jun; 74(6):632-640. PubMed ID: 28403383
[TBL] [Abstract][Full Text] [Related]
15. Reversal of Nicotine Withdrawal Signs Through Positive Allosteric Modulation of α4β2 Nicotinic Acetylcholine Receptors in Male Mice.
Hamouda AK; Jackson A; Bagdas D; Imad Damaj M
Nicotine Tob Res; 2018 Jun; 20(7):903-907. PubMed ID: 29059422
[TBL] [Abstract][Full Text] [Related]
16. Effects of varenicline on smoking cue–triggered neural and craving responses.
Franklin T; Wang Z; Suh JJ; Hazan R; Cruz J; Li Y; Goldman M; Detre JA; O'Brien CP; Childress AR
Arch Gen Psychiatry; 2011 May; 68(5):516-26. PubMed ID: 21199958
[TBL] [Abstract][Full Text] [Related]
17. Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette.
Brody AL; Mandelkern MA; Costello MR; Abrams AL; Scheibal D; Farahi J; London ED; Olmstead RE; Rose JE; Mukhin AG
Int J Neuropsychopharmacol; 2009 Apr; 12(3):305-16. PubMed ID: 18706128
[TBL] [Abstract][Full Text] [Related]
18. Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain.
Hussmann GP; DeDominicis KE; Turner JR; Yasuda RP; Klehm J; Forcelli PA; Xiao Y; Richardson JR; Sahibzada N; Wolfe BB; Lindstrom J; Blendy JA; Kellar KJ
J Neurochem; 2014 May; 129(4):721-31. PubMed ID: 24422997
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent effects of Varenicline on tobacco craving and withdrawal in tobacco smokers with and without schizophrenia.
Johnstone S; Sorkhou M; Rabin RA; George TP
Drug Alcohol Depend; 2022 May; 234():109412. PubMed ID: 35395548
[TBL] [Abstract][Full Text] [Related]
20. A single administration of low-dose varenicline saturates α4β2* nicotinic acetylcholine receptors in the human brain.
Lotfipour S; Mandelkern M; Alvarez-Estrada M; Brody AL
Neuropsychopharmacology; 2012 Jun; 37(7):1738-48. PubMed ID: 22395733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
